more_reports
MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt

MindBio Therapeutics Corp.

LinkedIn We are an innovation company that explores and creates. Through rigorous research and clinical trials, we're building prediction technologies to optimize human health and wellness. We are developing Edge AI hardware-software solutions for the scalable testing of drug and alcohol intoxication.
MBIO:CSE MBQIF:OTCQB WF6:Frankfurt

MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and paid a fee for this company profile page. Please refer to the important disclosures below for additional details.



Important Disclosures
MindBio Therapeutics Corp. is a Billboard advertiser of Streetwise Reports and pays a flat fee. Fees fund both sponsor-specific activities and general report activities. Sponsor-specific activities may include aggregating content and publishing that content on the Streetwise Reports site, creating and maintaining company landing pages, interviewing key management, posting a banner/billboard, and/or issuing press releases. The fees also cover the costs for Streetwise Reports to publish and syndicate investment opinion and comments, and also to curate or create sector-specific content. Billboard advertising monthly fees range from $3,000 to $5,000. This landing page contains a summary of the company that was prepared by that company. Some landing pages contain investing highlights and a catalyst calendar that are prepared by that company. The Expert Comments and Experts Following This Company sections of the landing page are compiled by Streetwise Reports. There may be other information about the company that is not placed on the landing page, and Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on the landing page. Readers should conduct their own research for all information publicly available concerning the company. This landing page may be considered advertising for the purposes of 18 U.S.C. 1734.

streetwise book logo Streetwise Company Fact Sheet

2026/3/15 14:42:45

(MBIO:CSE - MBQIF:OTCQB - WF6:Frankfurt)

Investing Highlights
 
MindBio uniquely uses the human voice as a diagnostic tool for screening drug and alcohol intoxication
 
It is at the forefront of AI and speech analytics in this regard being commercially ready with its Booze AI consumer product and the Q2 launch of its Edge AI Enterprise Kiosks for deployment in the mining industry.
 
Expected Q2 2026 testing of Edge AI Kiosks in mining industry, currently in development
 
Tight capital structure, only 4.7mill shares on issue, pre the current raise, post raise under 6 million shares on issue
catalyst Calendar
Q1
2026
Completion of new data collection and analysis technology, now.
Q2
2026
First testing of Edge AI Intox Detection Kiosks in mining industry Q2. 2026
MindBio Therapeutics Corp. Content